Oragenics, Inc.

187 articles with Oragenics, Inc.

• Oragenics to Participate at the World Vaccine Congress Washington 2022

  4/18/2022

  Oragenics, Inc. announced that Kimberly Murphy, a member of the Company’s Board of Directors, will attend the upcoming World Vaccine Congress Washington that will be held on April 18-22 to showcase the Company’s lead product, NT-CoV2-1, an intranasal vaccine candidate, and to pursue business development opportunities.

• Oragenics Initiates a Pivotal IND-Enabling Toxicology Study on its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1

  3/22/2022

  Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) today announced the initiation of a Good Laboratory Practice (GLP) toxicology study to evaluate the safety profile and immunogenicity of its NT-CoV2-1 vaccine candidate in rabbits.

• Oragenics Engages KBI Biopharma to Support Development of Intranasal COVID-19 Vaccine Candidate NT-CoV2-1

  3/10/2022

  Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) today announced it has entered into an agreement with KBI Biopharma, Inc. (“KBI”) for the process transfer, process optimization and cGMP manufacturing of the Company’s intranasal vaccine candidate NT-CoV2-1.

• Oragenics Extends Collaboration with the National Research Council of Canada to Develop Vaccine against the Omicron Variant

  12/20/2021

  Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) today announced it has extended a licensing and collaboration agreement with the National Research Council of Canada (NRC) that will enable Oragenics to pursue an intranasal vaccine designed to protect against the SARS-CoV-2 Omicron variant.

• Oragenics to Participate in Virtual Fireside Chat Hosted by Alliance Global Partners

  12/9/2021

  Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) today announced that the Company will participate in Alliance Global Partners’ (AGP) Virtual Series on Tuesday December 14, 2021 at 1:00 p.m. Eastern time.

• Oragenics Co-Authors a Publication Describing the Dual Mechanism of Action of Lantibiotics

  12/8/2021

  Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) in collaboration with researchers from Florida International University’s Department of Physics and Biomolecular Sciences Institute, today announced the publication of a study entitled “Lipid II Binding and Transmembrane Properties of Various Antimicrobial Lanthipeptides.”

• Oragenics Announces Positive COVID-19 Challenge Study Results Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate

  12/1/2021

  Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) today announced the results from its study to evaluate the immunogenicity and viral load reduction impact of its SARS-CoV-2 vaccine candidate in a hamster challenge study.

• Oragenics Awarded a $250,000 Grant from the National Institute of General Medical Sciences (NIGMS) for the Continued Research and Development of Lantibiotics.

  10/4/2021

  Oragenics, Inc. today announced that it was awarded a small business innovation research grant in the amount of $250,000 (“Computer-aided Design for Improved Lantibiotics” R41GM136034) for the Company’s continued research and development of lantibiotics, including its collaborative program with the Biomolecular Sciences Institute at Florida International University

• Oragenics Initiates COVID-19 Challenge Study Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate

  9/15/2021

  Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) today announced the initiation of a study to evaluate the immunogenicity and viral load reduction impact of its SARS-CoV-2 vaccine candidate in a hamster challenge study.

• Oragenics’ SARS-CoV-2 Spike Protein Produces Neutralizing Antibodies in Mice with Intramuscular and Intranasal Adjuvants

  8/30/2021

  Oragenics, Inc. announces that the stabilized pre-fusion spike protein trimer produced by its Canadian collaborator and licensed by the Company from the National Institutes of Health (NIH) generates neutralizing antibodies in mice after immunization against SARS-CoV-2, when administered with several novel intramuscular and intranasal adjuvants.

• Oragenics Announces Postponement of Annual Meeting of Shareholders

  8/24/2021

  Oragenics, Inc. today announced the Company’s reconvened annual meeting of shareholders, on August 23, 2021 at 4:00 p.m. was adjourned due to a lack of quorum.

• Oragenics Enters into Licensing Agreement with the National Research Council of Canada, to Pursue the Rapid Development of Next-Generation SARS-CoV-2 Vaccines

  7/27/2021

  Oragenics, Inc. announced it has entered into a licensing agreement with the National Research Council of Canada that will enable Oragenics to pursue the rapid development of next-generation vaccines against the SARS-CoV-2 virus and its variants.

• Oragenics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum

  7/1/2021

  Oragenics, Inc. announced that the Company’s annual meeting of shareholders, on June 30, 2021, at 9:00 a.m. was convened and adjourned, without any business being conducted, due to lack of the required quorum.

• Oragenics Issues Letter to Shareholders

  5/18/2021

  Executive Chairman Affirms Company Direction with Commitment to Speedy Execution of Business Strategy Highlights Deep Bench Strength Among Management, Board and Advisors in Vaccine Development and in Life Sciences

• Oragenics Announce Changes in Management and Board of Directors

  5/3/2021

  Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced that on May 2, 2021, Dr. Alan Joslyn resigned as Chief Executive Officer, President and director of Oragenics, Inc. to pursue other opportunities.

• Oragenics Enters into Material Transfer Agreement with Biodextris for Mucosal Adjuvant for Intranasal COVID-19 Vaccine

  3/9/2021

  Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced it has entered into a material transfer agreement with Biodextris Inc. for the use of three intranasal mucosal adjuvants in the Company’s Terra CoV-2 vaccine against COVID-19. Adjuvants are added to vaccines to enhance their immunogenicity. BDX100, BDX300 and BDX301 are proteosome-based adjuvants comprised of proteins and lipopolysaccharides

• Oragenics to Participate in Two Investment Conferences During March

  3/8/2021

  Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), today announced that Alan Joslyn, Ph.D., President and Chief Executive Officer of Oragenics, will participate in two virtual investment conferences during the month of March, as follows: The H.C. Wainwright Global Life Sciences Virtual Conference with one-on-one meetings being held March 9-10, 2021

• Oragenics Announces Recent Capital Raise and Warrant Exercises Totaling $21.9 Million and the Redemption of Its Series C Preferred Stock

  2/12/2021

  Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced it has raised approximately $20 million from the sale of common stock through a sales agreement with A.G.P./Alliance Global Partners for an “at-the-market” facility. In addition, the Company also received approximately $1.9 million from the exercise of common stock warrants.

• SARS-CoV-2 Spike Protein Licensed by Oragenics from the NIH Demonstrates Protective Immunity in Mice

  2/2/2021

  Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announces that the stabilized pre-fusion spike protein CoV-2 S-2P created by the National Institutes of Health (“NIH”) and licensed by the Company demonstrates protective immunity in immunized mice challenged with mouse-adapted SARS-CoV-2 virus.

• Oragenics Issues Letter to Stockholders

  1/14/2021

  Oragenics, Inc. (NYSE American: OGEN) today issued the following letter to stockholders from its President and Chief Executive Officer, Alan Joslyn, Ph.D.: To My Fellow Stockholders, With so much encouraging news recently around COVID-19 vaccine development, this is an excellent time to update